Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Says Preclinical Results of TNX-1900 Are Ready For Presentation through a Virtual Conference

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Announces says it is ready to make public the results from preclinical results of TNX-1900 (oxytocin solution for intranasal delivery). This will be done virtually and through a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference. According to the authors Michael Klukinov, David Yeomans, and Shashidhar H Kori, the poster presentations will be availed starting at 4:00 p.m. ET, Friday, July 31, 2020.

Tonix’s Portfolio Primarily Comprises of Central Nervous System (CNS) Product Candidates

The company has been at the frontline in the identification of new and promising product treatment candidates. The primary focus of its candidates has been the central nervous system (CNS) besides taking on immunology product candidates. Some of the vaccines in the latter category include those which prevent infectious, autoimmune, and cancer diseases while the CNS portfolio includes vaccines for serious psychiatric, pain, and addiction conditions.

The company is hopeful of promising data from animal studies of TNX-1800 before the end of the year. This is a lead vaccine candidate and primarily a live replicating vaccine based on the horsepox viral vector platform.

Other candidates in the preclinical pipeline include TNX-1500, TNX-1600, and TNX-1500. The three will treat different conditions even though none of them has been approved yet.

Tonix’s agreement with Trigemina, Inc.

Through an exclusive agreement, Tonix will acquire Trigemina’s migraine and pain treatment technologies. This means taking ownership of some of the licenses for some of the technologies, resulting in the development of TNX-1900.

This is a lead asset and an enhanced formulation of nasal oxytocin. It has been earmarked as a non-addictive treatment for migraine and craniofacial pain, according to Tonix’s CEO, Seth Lederman.

He emphasized that the data collected to date has been promising and has demonstrated the potential of oxytocin in blocking the release of the neurotransmitter calcitonin gene-related peptide (CGRP). The good news is that the FDA has endorsed oxytocin for pregnant women to induce labor.

Trigemina’s Chief Medical Officer Shashidar H. Kori says that their partnership with Tonix demonstrates their dedication n pursuing the development of alternative treatments for migraines.